1. Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
    Etienne Giroux-Leprieur et al, 2018, International Journal of Molecular Sciences CrossRef
  2. Long non‐coding RNA colon cancer‐associated transcript‐1 regulates tumor cell proliferation and invasion of non‐small‐cell lung cancer through suppressing miR‐152
    Na Li et al, 2020, Geriatrics & Gerontology International CrossRef
  3. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1
    Hai-Xiang Gao et al, 2016, Molecular Medicine Reports CrossRef
  4. Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
    Venus Sosa Iglesias et al, 2018, Frontiers in Oncology CrossRef
  5. Retracted: LncRNA ATB promotes proliferation and metastasis in A549 cells by down‐regulation of microRNA‐494
    Yiwei Cao et al, 2018, Journal of Cellular Biochemistry CrossRef
  6. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
    Zachary Schrank et al, 2018, Cancers CrossRef
  7. Anti-migratory effect of curcumin on A-549 lung cancer cells via epigenetic reprogramming of RECK/ matrix metalloproteinase axis
    Shabnam Mostofi et al, 2022, Hormone Molecular Biology and Clinical Investigation CrossRef
  8. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1
    Claudia Voena et al, 2016, Oncotarget CrossRef
  9. Crizotinib resistance: implications for therapeutic strategies
    I. Dagogo-Jack et al, 2016, Annals of Oncology CrossRef
  10. Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions
    Julien Ancel et al, 2022, Cells Tissues Organs CrossRef
  11. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
    Robert Vander Velde et al, 2020, Nature Communications CrossRef
  12. Potential monoamine oxidase A inhibitor suppressing paclitaxel‐resistant non‐small cell lung cancer metastasis and growth
    Xiaoguang Yang et al, 2020, Thoracic Cancer CrossRef
  13. A tool for discovering drug sensitivity and gene expression associations in cancer cells
    Yong Qin et al, 2017, PLOS ONE CrossRef
  14. Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy
    Ebru Güçlü et al, 2021, Medical Oncology CrossRef
  15. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
    Lucy Hare et al, 2021, Cancers CrossRef
  16. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
    Shana Claeys et al, 2017, Oncotarget CrossRef
  17. The Molecular Role of IL-35 in Non-Small Cell Lung Cancer
    Yuqiu Hao et al, 2022, Frontiers in Oncology CrossRef
  18. Hypoxia in Lung Cancer Management: A Translational Approach
    Julien Ancel et al, 2021, Cancers CrossRef
  19. Low expression of miR-192 in NSCLC and its tumor suppressor functions in metastasis via targeting ZEB2
    Zhang Yunxia et al, 2016, Open Life Sciences CrossRef
  20. MicroRNA-1285-5p influences the proliferation and metastasis of non-small-cell lung carcinoma cells via downregulating CDH1 and Smad4
    Shixia Zhou et al, 2017, Tumor Biology CrossRef
  21. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway
    HAI JIN et al, 2015, Oncology Reports CrossRef
  22. Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer
    Rodolfo Chicas-Sett et al, 2023, Lung Cancer Diagnosis and Treatment: An Interdisciplinary Approach CrossRef
  23. Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism
    Abhilasha Sharma et al, 2022, Frontiers in Genetics CrossRef
  24. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
    Francesco Facchinetti et al, 2017, Mechanisms of Drug Resistance in Cancer Therapy CrossRef
  25. Research Progress on the Drug Resistance of ALK Kinase Inhibitors
    Zhen Li et al, 2022, Current Medicinal Chemistry CrossRef
  26. Association of mutation profiles with metastasis in patients with non-small cell lung cancer
    Yingxue Li et al, 2024, Frontiers in Oncology CrossRef
  27. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
    Srividya Srinivasamaharaj et al, 2016, Expert Review of Anticancer Therapy CrossRef
  28. Understanding and targeting resistance mechanisms in NSCLC
    Julia Rotow et al, 2017, Nature Reviews Cancer CrossRef
  29. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
    Kajetan Kiełbowski et al, 2023, Frontiers in Pharmacology CrossRef
  30. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
    Gouji Toyokawa et al, 2015, Oncology Research and Treatment CrossRef
  31. GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization
    Zhixin Li et al, 2020, Functional & Integrative Genomics CrossRef
  32. Modalités d’utilisation du ceritinib (Zykadia™), inhibiteur de ALK de 2e génération, dans le cancer bronchique non à petites cellules de stade avancé
    Etienne Giroux Leprieur et al, 2015, Bulletin du Cancer CrossRef
  33. p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA‐320a in lung cancer
    Aimin Xing et al, 2018, Thoracic Cancer CrossRef
  34. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
    Delphine Antoni et al, 2021, Cancers CrossRef
  35. Lung Cancer Management with Silibinin: A Historical and Translational Perspective
    Sara Verdura et al, 2021, Pharmaceuticals CrossRef
  36. A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies
    Mengwei Ni et al, 2020, BMC Complementary Medicine and Therapies CrossRef
  37. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines
    Yanqiong Chen et al, 2018, Anti-Cancer Drugs CrossRef
  38. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma
    Yosuke Kamide et al, 2015, Internal Medicine CrossRef
  39. Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
    Xing Chang et al, 2019, RSC Advances CrossRef
  40. Targeting hypoxic response for cancer therapy
    Elisa Paolicchi et al, 2016, Oncotarget CrossRef
  41. Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
    Sara Verdura et al, 2022, Cancers CrossRef
  42. Notch Transduction in Non-Small Cell Lung Cancer
    Amnah Sharif et al, 2020, International Journal of Molecular Sciences CrossRef
  43. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
    Mariam Elshatlawy et al, 2023, Molecular Oncology CrossRef
  44. PRPS2 Enhances Resistance to Cisplatin via Facilitating Exosomes-mediated Macrophage M2 Polarization in Non-small Cell Lung Cancer
    Gaohua Liu et al, 2022, Immunological Investigations CrossRef
  45. Mechanistic Understanding of Curcumin’s Therapeutic Effects in Lung Cancer
    Wan Nur Baitty Wan Mohd Tajuddin et al, 2019, Nutrients CrossRef
  46. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
    Yuichi Ozawa et al, 2024, Therapeutic Advances in Medical Oncology CrossRef